BiomX (PHGE) Non-Current Debt (2018 - 2023)
BiomX (PHGE) posted Non-Current Debt of $5.4 million for Q4 2023, down 55.24% sequentially from $12.1 million in Q3 2023, and down 48.99% YoY from $10.6 million in Q4 2022.
BiomX (PHGE) Non-Current Debt (2018 - 2023) Analysis & Trends
BiomX has reported Non-Current Debt for 6 years, with the latest figure at $5.4 million in Q4 2023.
- Quarterly Non-Current Debt fell 48.99% year-over-year to $5.4 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $5.4 million (down 48.99% YoY) and the FY2023 annual result came in at $5.4 million, down 48.99% from the prior year.
- Non-Current Debt slipped to $5.4 million in Q4 2023 per PHGE's latest filing, from $12.1 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $15.0 million in Q2 2022 and troughed at $500000.0 in Q1 2019.
- A 5-year average of $7.6 million and a median of $5.4 million in 2023 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2021 and 2023: Non-Current Debt surged 633.68% in 2021, then tumbled 48.99% in 2023.
- Over 5 years, Non-Current Debt stood at $856000.0 in 2019, then soared by 487.85% to $5.0 million in 2020, then jumped by 186.37% to $14.4 million in 2021, then retreated by 26.5% to $10.6 million in 2022, then tumbled by 48.99% to $5.4 million in 2023.
- According to Business Quant data, Non-Current Debt over the past three periods registered $5.4 million, $12.1 million, and $8.2 million for Q4 2023, Q3 2023, and Q2 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 546.77 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 8.96 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.97 Mn |
| 10 | BiomX | 361,408.40 | -806,591.60 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 5.40 Mn |
| Sep 30, 2023 | 12.07 Mn |
| Jun 30, 2023 | 8.16 Mn |
| Mar 31, 2023 | 14.58 Mn |
| Dec 31, 2022 | 10.59 Mn |
| Sep 30, 2022 | 15.00 Mn |
| Jun 30, 2022 | 15.00 Mn |
| Mar 31, 2022 | 14.10 Mn |
| Dec 31, 2021 | 14.41 Mn |
| Sep 30, 2021 | 14.23 Mn |
| Jun 30, 2021 | 4.88 Mn |
| Mar 31, 2021 | 4.74 Mn |
| Dec 31, 2020 | 5.03 Mn |
| Sep 30, 2020 | 3.91 Mn |
| Jun 30, 2020 | 665,000.00 |
| Mar 31, 2020 | 740,000.00 |
| Dec 31, 2019 | 856,000.00 |
| Jun 30, 2019 | 500,000.00 |
| Mar 31, 2019 | 500,000.00 |
| Dec 31, 2018 | 500,000.00 |